Efficacy of Doxycycline Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections Among People with or Without HIV: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Systematic Review
DOI:
https://doi.org/10.55175/cdk.v53i09.2210Kata Kunci:
Doxycycline, HIV, meta-analysis, post-exposure prophylaxis, pre-exposure prophylaxis, sexually transmitted infectionsAbstrak
Introduction: Bacterial sexually transmitted infections (STIs) remain a significant burden among populations at high risk, including people living with HIV (PLWH) and HIV-negative individuals receiving HIV pre-exposure prophylaxis (PrEP). This study evaluated the efficacy and safety of doxycycline pre- and post-exposure prophylaxis for preventing bacterial STIs among people with or without HIV. Methods: This systematic review followed PRISMA 2020 guidelines and was prospectively registered in PROSPERO (CRD420251171815). We conducted comprehensive searches in PubMed, Embase, and Cochrane CENTRAL through October 2025. We included randomized controlled trials evaluating doxycycline prophylaxis versus standard care. Meta-analysis was performed using random-effects models in RevMan 5.4. Results: Seven randomized controlled trials (2,091 participants) were included. Doxycycline prophylaxis significantly reduced bacterial STI incidence by 57% (pooled RR 0.43, 95% CI 0.35–0.53; p < 0.00001; I² = 42%). In the subgroup analysis of HIV-positive participants, doxycycline achieved a 62% reduction (RR 0.38; 95% CI 0.28–0.52). Pathogen-specific analysis showed a 72% reduction for chlamydia (RR 0.28), a 72% reduction for syphilis (RR 0.28), and a 44% reduction for gonorrhea (RR 0.56). Safety outcomes were summarized descriptively, with gastrointestinal symptoms most frequently reported; no pooled adverse-event or discontinuation estimate was calculated. The number needed to treat calculated from pooled event counts was approximately 4. Conclusion: Doxycycline prophylaxis reduced bacterial STI incidence in high-risk populations with and without HIV. These findings support considering doxycycline prophylaxis as a prevention strategy, while emphasizing limitations in regimen-specific evidence and the need for ongoing safety and antimicrobial-resistance monitoring.
Unduhan
Referensi
Elendu C, Amaechi DC, Elendu ID, Elendu TC, Amaechi EC, Usoro EU, et al. Global perspectives on the burden of sexually transmitted diseases: narrative review. Medicine 2024;103(20):e38199. https://doi.org/10.1097/MD.0000000000038199.
Tuan J, Goheen MM, Trebelcock W, Dunne D. Sexually transmitted infections in people with HIV. Infect Dis Clin North Am. 2024;38(3):559–79. https://doi.org/10.1016/j.idc.2024.04.007.
Singh V, Kumar A, Gupta S. Mental health prevention and promotion— narrative review. Front Psychiatry 2022;13:898009. https://doi.org/10.3389/fpsyt.2022.898009.
Weir BW, Wirtz AL, Chemnasiri T, Baral SD, Decker M, Dun C, et al. High PrEP uptake, adherence, persistence and effectiveness outcomes among young Thai men and transgender women who sell sex in Bangkok and Pattaya, Thailand: findings from the open-label combination HIV prevention effectiveness (COPE) study. Lancet Regional Health - Southeast Asia 2023;15:100217. doi: 10.1016/j.lansea.2023.100217.
Brunner P, Brunner K, Kübler D. The cost-effectiveness of HIV/STI prevention in high-income countries with concentrated epidemic settings: a scoping review. AIDS Behav. 2022;26(7):2279–97. https://doi.org/10.1007/s10461-022-03583-y.
Cannon CA, Celum CL. Doxycycline postexposure prophylaxis for prevention of sexually transmitted infections. Top Antivir Med. 2023;31(5):566–75. PMID: 38198668.
Bachmann LH, Barbee LA, Chan P, Reno H, Workowski KA, Hoover K, et al. CDC clinical guidelines on the use of doxycycline postexposure prophylaxis for bacterial sexually transmitted infection prevention, United States, 2024. MMWR Recomm Rep. 2024;73(2):1–8. https://doi.org/10.15585/mmwr.rr7302a1.
Traeger MW, Leyden WA, Volk JE, Silverberg MJ, Horberg MA, Davis TL, et al. Doxycycline postexposure prophylaxis and bacterial sexually transmitted infections among individuals using HIV preexposure prophylaxis. JAMA Intern Med. 2025;185(3):273–81. https://doi.org/10.1001/jamainternmed.2024.7186.
Sterne JAC, Savovi J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.
Tantry TP, Karanth H, Shetty PK, Kadam D. Self-learning software tools for data analysis in meta-analysis. Korean J Anesthesiol. 2021;74(5):459–61. https://doi.org/10.4097/kja.21080.
Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med. 2023;388(14):1296–306. https://doi.org/10.1056/NEJMoa2211934.
Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18(3):308–17. https://doi.org/10.1016/S1473-3099(17)30725-9.
Molina JM, Bercot B, Assoumou L, Rubenstein E, Algarte-Genin M, Pialoux G, et al. Doxycycline prophylaxis and meningococcal group vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design. Lancet Infect Dis. 2024;24(10):1093–104. https://doi.org/10.1016/S1473-3099(24)00236-6.
Stewart J, Oware K, Donnell D, Violette LR, Odoyo J, Soge OO, et al. Doxycycline prophylaxis to prevent sexually transmitted infections in women. N Engl J Med. 2023;389(25):2331–40. https://doi.org/10.1056/NEJMoa2304007.
Grennan T, Mohammed S, Edward J, Tattersall T, Gupta AK, Seto J, et al. A pilot, randomized controlled trial of dual daily HIV and sexually transmitted infection pre-exposure prophylaxis using tenofovir disoproxil fumarate/emtricitabine and doxycycline in gay, bisexual, and other men who have sex with men and transgender women: the DuDHS study. Clin Infect Dis. 2025;82(6):1054–62 . https://doi.org/10.1093/cid/ciaf043.
Bolan RK, Beymer MR, Weiss RE, Flynn RP, Leibowitz AA, Klausner JD. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. Sex Transm Dis. 2015;42(2):98–103. https://doi.org/10.1097/OLQ.0000000000000216.
Luetkemeyer AF, Donnell D, Cohen SE, Grabow C, Dombrowski JC, Buchbinder SP, et al. Doxycycline to prevent bacterial sexually transmitted infections in the USA: final results from the DoxyPEP multicentre, open-label, randomised controlled trial and open-label extension. Lancet Infect Dis. 2025;25(8):873–83. https://doi.org/10.1016/S1473-3099(25)00085-4.
Szondy I, Meznerics FA, Lrincz K, Kemny LV, Walter A, Mohammed AA, et al. Doxycycline prophylaxis for the prevention of sexually transmitted infections: systematic review and meta-analysis of randomized controlled trials. Int J Infect Dis. 2024;147:107186. doi: 10.1016/j.ijid.2024.107186.
Grant JS, Stafylis C, Celum C, Grennan T, Haire B, Kaldor J, et al. Doxycycline prophylaxis for bacterial sexually transmitted infections. Clin Infect Dis. 2020;70(6):1247–53. https://doi.org/10.1093/cid/ciz866.
Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187. https://doi.org/10.15585/mmwr.rr7004a1.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2026 Dykall Dzikri, Flora Ramona Sigit Prakoeswa, Vinka Dwi Anggita
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
